- Home
- MIRM vs WB Comparison
MIRM vs WB Comparison
Compare MIRM & WB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- WB
- Stock Information
- Founded
- MIRM 2018
- WB 2009
- Country
- MIRM United States
- WB China
- Employees
- MIRM N/A
- WB N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- WB Computer Software: Programming Data Processing
- Sector
- MIRM Health Care
- WB Technology
- Exchange
- MIRM Nasdaq
- WB Nasdaq
- Market Cap
- MIRM 3.3B
- WB 2.8B
- IPO Year
- MIRM 2019
- WB 2014
- Fundamental
- Price
- MIRM $76.06
- WB $11.71
- Analyst Decision
- MIRM Strong Buy
- WB Buy
- Analyst Count
- MIRM 9
- WB 2
- Target Price
- MIRM $73.89
- WB $14.00
- AVG Volume (30 Days)
- MIRM 914.8K
- WB 1.4M
- Earning Date
- MIRM 08-06-2025
- WB 08-14-2025
- Dividend Yield
- MIRM N/A
- WB 14.02%
- EPS Growth
- MIRM N/A
- WB 9.65
- EPS
- MIRM N/A
- WB 1.41
- Revenue
- MIRM $429,161,000.00
- WB $1,762,960,000.00
- Revenue This Year
- MIRM $52.71
- WB $1.33
- Revenue Next Year
- MIRM $19.71
- WB $2.25
- P/E Ratio
- MIRM N/A
- WB $8.16
- Revenue Growth
- MIRM 62.33
- WB 1.37
- 52 Week Low
- MIRM $36.86
- WB $7.03
- 52 Week High
- MIRM $76.40
- WB $12.40
- Technical
- Relative Strength Index (RSI)
- MIRM 77.75
- WB 62.22
- Support Level
- MIRM $73.12
- WB $11.15
- Resistance Level
- MIRM $76.02
- WB $11.83
- Average True Range (ATR)
- MIRM 2.39
- WB 0.32
- MACD
- MIRM 0.04
- WB 0.01
- Stochastic Oscillator
- MIRM 96.66
- WB 75.93
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About WB Weibo Corporation
Weibo Corp is a China-based company mainly engaged in the social media advertising business for people to create, discover and distribute content. The company's activities include Advertising and Marketing, which mainly provides a full range of advertising customization and marketing solutions. The Value-added Services mainly provide services such as membership services on social platforms, online games, live broadcasts, social e-commerce, and others. The Company's main product is the social platform Weibo.